D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 100 Citations 50,153 544 World Ranking 3756 National Ranking 2133

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Gene

Massimo Cristofanilli focuses on Internal medicine, Breast cancer, Oncology, Cancer and Metastatic breast cancer. His work in Internal medicine tackles topics such as Surgery which are related to areas like Confidence interval. His research integrates issues of Metastasis, Circulating tumor cell and Pathology in his study of Breast cancer.

His biological study spans a wide range of topics, including Survival rate, Palbociclib, Fulvestrant, Disease and CA15-3. His Cancer research is multidisciplinary, incorporating elements of Cancer research, Gynecology and Immunology. His Metastatic breast cancer study combines topics from a wide range of disciplines, such as Whole blood, Phases of clinical research, Neoplasm, Placebo and Prospective cohort study.

His most cited work include:

  • Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer (3458 citations)
  • Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer (1820 citations)
  • Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy (1509 citations)

What are the main themes of his work throughout his whole career to date?

Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer are his primary areas of study. Massimo Cristofanilli regularly ties together related areas like Surgery in his Internal medicine studies. His Oncology research is multidisciplinary, relying on both Trastuzumab, Proportional hazards model, CA15-3, Hazard ratio and Stage.

He interconnects Cancer research, Metastasis and Pathology in the investigation of issues within Breast cancer. His research on Cancer frequently connects to adjacent areas such as Gynecology. Within one scientific family, Massimo Cristofanilli focuses on topics pertaining to Circulating tumor cell under Metastatic breast cancer, and may sometimes address concerns connected to Liquid biopsy.

He most often published in these fields:

  • Internal medicine (61.30%)
  • Oncology (55.81%)
  • Breast cancer (56.70%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (61.30%)
  • Breast cancer (56.70%)
  • Oncology (55.81%)

In recent papers he was focusing on the following fields of study:

His primary areas of investigation include Internal medicine, Breast cancer, Oncology, Cancer and Cancer research. His work on Placebo expands to the thematically related Internal medicine. His biological study focuses on Inflammatory breast cancer.

Massimo Cristofanilli works mostly in the field of Oncology, limiting it down to topics relating to Hormone receptor and, in certain cases, Human Epidermal Growth Factor Receptor 2, as a part of the same area of interest. The concepts of his Cancer study are interwoven with issues in Biomarker, Prospective cohort study and Exact test. His work in Cancer research addresses issues such as Circulating tumor cell, which are connected to fields such as Liquid biopsy, Targeted therapy, Chemotherapy and Epithelial cell adhesion molecule.

Between 2017 and 2021, his most popular works were:

  • Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (308 citations)
  • The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial (154 citations)
  • Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. (148 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

His scientific interests lie mostly in Internal medicine, Oncology, Breast cancer, Cancer and Cancer research. His Internal medicine study typically links adjacent topics like Placebo. The study incorporates disciplines such as Palbociclib, Proportional hazards model, Fulvestrant, Hazard ratio and Triple-negative breast cancer in addition to Oncology.

Massimo Cristofanilli combines subjects such as Survival rate, Inflammation, Circulating tumor DNA and Circulating tumor cell with his study of Breast cancer. His Cancer study incorporates themes from Polymerase chain reaction and DNA repair. His study in Cancer research is interdisciplinary in nature, drawing from both Germline, Targeted therapy, Kinase, Lung cancer and Prostate cancer.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer

Massimo Cristofanilli;G. Thomas Budd;Matthew J. Ellis;Alison Stopeck.
The New England Journal of Medicine (2004)

4519 Citations

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

Cornelia Liedtke;Chafika Mazouni;Kenneth R. Hess;Fabrice André.
Journal of Clinical Oncology (2008)

2786 Citations

Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

Roman Rouzier;Charles M. Perou;W. Fraser Symmans;Nuhad Ibrahim.
Clinical Cancer Research (2005)

2296 Citations

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser.
Journal of Clinical Oncology (2005)

1527 Citations

Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System

Sabine Riethdorf;Herbert Fritsche;Volkmar Müller;Thomas Rau.
Clinical Cancer Research (2007)

1325 Citations

Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer

Massimo Cristofanilli;Daniel F. Hayes;G. Thomas Budd;Mathew J. Ellis.
Journal of Clinical Oncology (2005)

1209 Citations

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi.
The New England Journal of Medicine (2015)

1198 Citations

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro.
Lancet Oncology (2016)

1179 Citations

Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival

Daniel F. Hayes;Massimo Cristofanilli;G. Thomas Budd;Matthew J. Ellis.
Clinical Cancer Research (2006)

1074 Citations

Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer

G. Thomas Budd;Massimo Cristofanilli;Mathew J. Ellis;Allison Stopeck.
Clinical Cancer Research (2006)

867 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Massimo Cristofanilli

Gabriel N. Hortobagyi

Gabriel N. Hortobagyi

The University of Texas MD Anderson Cancer Center

Publications: 188

Lajos Pusztai

Lajos Pusztai

Yale University

Publications: 159

Klaus Pantel

Klaus Pantel

Universität Hamburg

Publications: 159

Francisco J. Esteva

Francisco J. Esteva

New York University

Publications: 87

Jorge S. Reis-Filho

Jorge S. Reis-Filho

Memorial Sloan Kettering Cancer Center

Publications: 85

Giuseppe Viale

Giuseppe Viale

European Institute of Oncology

Publications: 84

Eric P. Winer

Eric P. Winer

Harvard University

Publications: 82

Martine Piccart

Martine Piccart

Université Libre de Bruxelles

Publications: 80

Fabrice Andre

Fabrice Andre

Institut Gustave Roussy

Publications: 77

Giuseppe Curigliano

Giuseppe Curigliano

European Institute of Oncology

Publications: 76

Henry Mark Kuerer

Henry Mark Kuerer

The University of Texas MD Anderson Cancer Center

Publications: 74

Vicente Valero

Vicente Valero

The University of Texas MD Anderson Cancer Center

Publications: 74

Funda Meric-Bernstam

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

Publications: 74

Kelly K. Hunt

Kelly K. Hunt

The University of Texas MD Anderson Cancer Center

Publications: 67

Ana M. Gonzalez-Angulo

Ana M. Gonzalez-Angulo

The University of Texas MD Anderson Cancer Center

Publications: 67

W. Fraser Symmans

W. Fraser Symmans

The University of Texas MD Anderson Cancer Center

Publications: 67

Something went wrong. Please try again later.